Combined hepatocellular carcinoma and cholangiocarcinoma
diseaseOn this page
Also known as carcinoma of liver and intrahepatic biliary tractcarcinoma of the liver and intrahepatic biliary tractCholangiohepatomacombined hepatocellular cancer and cholangiocarcinoma (bile duct cancer)combined hepatocellular cancer and intrahepatic bile duct cancer (cholangiocarcinoma)Hepatocholangiocarcinomaliver and intrahepatic biliary tract carcinomaMixed hepatocellular cholangiocarcinoma
Summary
Combined hepatocellular carcinoma and cholangiocarcinoma (MONDO:0044791) is a cancer and 5 clinical trials. Top therapeutic interventions include cisplatin. A subtype of adenocarcinoma of gallbladder and extrahepatic biliary tract — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: Unknown (Worldwide) [Orphanet-validated]
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | combined hepatocellular carcinoma and cholangiocarcinoma |
| Mondo ID | MONDO:0044791 |
| Orphanet | 529852 |
| ICD-11 | 1097637010, 1600108866, 894488488 |
| NCIT | C3828 |
| SNOMED CT | 274902006 |
| UMLS | C0221287 |
| MedGen | 113160 |
| GARD | 0022200 |
| Is cancer (heuristic) | yes |
Also known as: carcinoma of liver and intrahepatic biliary tract · carcinoma of the liver and intrahepatic biliary tract · Cholangiohepatoma · combined hepatocellular cancer and cholangiocarcinoma (bile duct cancer) · combined hepatocellular cancer and intrahepatic bile duct cancer (cholangiocarcinoma) · combined hepatocellular carcinoma and cholangiocarcinoma · Hepatocholangiocarcinoma · liver and intrahepatic biliary tract carcinoma · Mixed hepatocellular cholangiocarcinoma
Data availability: 2 cell lines.
Disease family
This is a subtype of adenocarcinoma of gallbladder and extrahepatic biliary tract. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease by body system or component › digestive system disorder › digestive system cancer › liver cancer › biliary tract cancer › bile duct cancer › bile duct carcinoma › extrahepatic bile duct carcinoma › extrahepatic bile duct adenocarcinoma › adenocarcinoma of gallbladder and extrahepatic biliary tract › combined hepatocellular carcinoma and cholangiocarcinoma
Related subtypes (1): cholangiocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05211323 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer |
| NCT07105748 | PHASE2 | RECRUITING | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) |
| NCT06541652 | Not specified | RECRUITING | A French Multicenter Observational Retrospective Study of Rare Primary Liver Cancers |
| NCT06849180 | Not specified | RECRUITING | Novel Subtypes and Treatment Strategies of Patients with Unresectable Combined Hepatocellular Cholangiocarcinoma Based on Multimodal Data |
| NCT02762721 | Not specified | COMPLETED | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 1 |
Related Atlas pages
- Drugs: Cisplatin